Investment Opportunity
A Proven Treatment.
A Clear Pathway.
Arianova Bio is seeking strategic investment to complete the FDA validation pathway for a herbal wound care ointment with a documented track record of success in Iran. We are not starting from scratch — we are bringing a proven solution to the world's largest healthcare market.
Request Investor DeckThe Market Opportunity
Chronic wound care is a massive, underserved market with growing demand for effective, natural alternatives.
Projected to exceed $20 billion by 2027, driven by diabetes and aging population
Americans suffering from chronic wounds, diabetic foot ulcers, and severe burns annually
Documented healing outcomes in Iranian patients using our herbal ointment formulation
Milestones & Roadmap
We have already achieved critical early milestones. Your investment accelerates the path to FDA approval.
Hundreds of patients treated for chronic wounds, diabetic foot ulcers, and burns with 1–3 week healing times.
University of Miami Venture Catalyst funding secured, validating our commercial potential.
Research partnership established at a world-class innovation center for in vitro validation.
Wound scratch assay, cell viability, proliferation, cytotoxicity, antimicrobial, and anti-inflammatory studies in progress.
Full in vitro data package required for FDA pre-submission meeting and IND application.
Formal engagement with FDA to align on approval pathway and clinical trial requirements.
U.S.-based clinical trials to confirm safety and efficacy for FDA approval.
Bring a proven, natural wound care solution to the multi-billion dollar U.S. wound care market.
Use of Funds
We are seeking $500,000 in seed funding to complete the FDA validation pathway and prepare for clinical trials.
Finalize all 6 validation assays at CIC St. Louis
Pre-submission meetings, IND application preparation
Protocol design, site selection, IRB approval
Patent filings, team expansion, overhead
Ready to Invest in the Future of Wound Care?
We welcome conversations with angel investors, family offices, biotech VCs, and strategic partners who share our vision of bringing proven, natural therapeutics to the U.S. market.